Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Umang Shah, Matthew C. Coffey, Himanshu Kharkwal, Sanjay Goel, Allyson J. Ocean, Sengottuvel Viswanathan, Imran Chaudhary, M. H. Ghalib, Ruwan Parakrama, Radhashree Maitra
Publikováno v:
Molecular Cancer Therapeutics. 19:1148-1156
KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is syn
Autor:
Ulivi Paola, Laura Matteucci, Milena Urbini, Alessandro Passardi, Gianluca Tedaldi, Giorgia Marisi, Matteo Canale, Giovanni Martinelli, Giovanni Luca Frassineti, Chiara Molinari
Publikováno v:
Cancer Research. 81:541-541
The use of liquid biopsy in the clinical management of colorectal cancer (CRC) patients is not yet a routine clinical practice, although it could give important information for tumor baseline characterization and for monitoring during treatment. In t
Autor:
Daniel I. Isaac, Ryan Ramaekers, Mark Erlander, Manish R. Sharma, Lawrence Mendelsohn, Maya Ridinger
Publikováno v:
Cancer Research. 81:425-425
Introduction: Chemotherapy in combination with targeted agents are standard-of-care options for first and second-line treatment of metastatic colorectal cancer (mCRC) patients. Second-line treatment of KRAS-mutated mCRC confers a dismal patient outco
Autor:
Tanios Bekaii-Saab, Errin Samuelsz, Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Mark G. Erlander, Heinz-Josef Lenz
Publikováno v:
Cancer Research. 80:CT235-CT235
Background: Chemotherapy in combination with targeted agents are standard-of-care options for patients for mCRC with response rates >50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower with respo
Autor:
Xueping Qu, Felipe De Sousa E Melo, Ling-Yuh Huw, Richard Bourgon, Joshua Thomas, Nnamdi Ihuegbu, Anneleen Daemen, Heinz-Josef Lenz, Radia M. Johnson, Fang-Shu Ou, Omar Kabbarah, Alan Venook, Ethan Sokol, Oliver A. Zill, Carlos Bais, Yvonne Kschonsak, Federico Innocenti
Publikováno v:
Cancer Research. 80:LB-063
Extensive biological and clinical evidence supports the notion many CRC tumors are addicted to EGFR/KRAS/MAPK signaling. For example, mutations in KRAS, BRAF and other MAPK pathway components confer intrinsic or acquired resistance to anti-EGFR thera
Autor:
Hiroyuki Uetake, Kohei Shitara, Takayuki Yoshino, Kei Muro, Kiwamu Akagi, Hirofumi Yasui, Jun Watanabe, Takeo Sato, Takeharu Yamanaka, Kentaro Yamazaki, Takeshi Kato, Manabu Shiozawa, Kazunori Yamanaka, Riu Yamashita, Eiji Oki, Victor E. Velculescu, Hisatsugu Ohori, Atsushi Ochiai, Junpei Soeda, Masamitsu Hihara, Yoshito Komatsu, Ikuo Mori, Katsuya Tsuchihara, Takeshi Naitoh
Publikováno v:
Cancer Research. 80:1974-1974
Introduction: We performed an exploratory analysis of circulating tumor DNA (ctDNA) in patients (pts) with RAS wild-type (WT) chemotherapy-naïve stage IV metastatic colorectal cancer (mCRC) from the ongoing phase III PARADIGM study (NCT02394834). Th
Autor:
Andrew Weickhardt, Diego D'Ávila Paskulin, Teresa Nguyen, Dara L. Aisner, Robert C. Doebele, Fiona Chionh, Niall C. Tebbutt, Jenny Hardingham, Anh T. Le, Nathan Schulte, Marileila Varella-Garcia, John M. Mariadason, Jerry Haney
Publikováno v:
Molecular Cancer Research. 12:111-118
Activated anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases, through gene fusions, have been found in lung adenocarcinomas and are highly sensitive to selective kinase inhibitors. This study aimed at identifying the presence of these rearran
Autor:
Erin S. Murphy, Yan Luo, Elizabeth Asque, Jeff Waring, Jordan Berlin, Cyril Ramathal, Peter Ansell, Lei He, Arne Jason Grundstad
Publikováno v:
Cancer Research. 79:4461-4461
Changes in plasma ctDNA are used as a surrogate molecular marker of response to determine clinical efficacy and provide insights into potential resistance mechanisms to targeted therapeutics. Detection of genomic alterations in circulating tumor DNA
Autor:
Christophe Tournigand, Virginie F. Mégalophonos, Pascale Cervera, Aude Battistella, Benoist Chibaudel, Sylvie Dumont, Pascaline Boudou, Thierry André, Jean-François Fléjou, Aimery de Gramont, Nyam Kamsu-Kom, Virginie Poindessous, Annette K. Larsen, Djamila Ouaret, Alexandre E. Escargueil, Amélie Petitprez, Karima El Ouadrani
Publikováno v:
Clinical Cancer Research. 17:6522-6530
Purpose: Epidermal growth factor receptor (EGFR) and VEGF(R) signaling show extensive cross-talk, providing a rationale for joint targeting of the two pathways. However, combinations of monoclonal antibodies (mAb) targeting EGFR and VEGF showed disap